Pierre Bigot1,2,3, Jean-Christophe Bernhard4,5,6, Inderbir S Gill7, Nam Son Vuong6, Grégory Verhoest5,8, Vincent Flamand5,9, Boris Reix9, Evren Suer10, Ilker Gökce10, Jean Baptiste Beauval4,5,11, François Xavier Nouhaud4,5,11, Masatoshi Eto12, Eduard Baco13, Toru Matsugasumi7, Yvonne Chowaniec14, Jérôme Rigaud4,14, Claire Lenormand15, Christian Pfister4,5,11, Jean François Hetet4,16, Guillaume Ploussard4,17, Morgan Roupret4,18,19, Priscilla Léon18, Adnan El Bakri20, Stéphane Larré4,20, Xavier Tillou21, Arnaud Doerfler21, Aurélien Descazeaud5,22, Nicolas Koutlidis23, Alexandre Schneider23, Philippe Sebe4,24, Alexandre Ingels25, Abdel Rahmène Azzouzi26, Michel Soulié4,5,11, Arnaud Méjean4,5,27, Karim Bensalah4,5,8, Jean-Jacques Patard4,5,25. 1. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France. pibigot@chu-angers.fr. 2. French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France. pibigot@chu-angers.fr. 3. Department of Urology, CHU Angers, Angers University Hospital, 4 rue Larrey, 49333, Angers, France. pibigot@chu-angers.fr. 4. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France. 5. French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France. 6. Department of Urology, Bordeaux University Hospital, Bordeaux, France. 7. USC Institute of Urology, University of Southern California, Los Angeles, CA, USA. 8. Department of Urology, Pontchaillou University Hospital, Rennes, France. 9. Department of Urology, Lille University Hospital, Lille, France. 10. Department of Urology, University Hospital of Ankara, Ankara, Turkey. 11. Department of Urology, Toulouse University Hospital, Toulouse, France. 12. Department of Urology, University Hospital of Kumamoto, Kumamoto, Japan. 13. Department of Urology, University Hospital of Oslo, Oslo, Norway. 14. Department of Urology, Nantes University Hospital, Nantes, France. 15. Department of Urology, Rouen University Hospital, Rouen, France. 16. Department of Urology, Clinique Jules Vernes, Nantes, France. 17. Department of Urology, Saint-Louis University Hospital, APHP, Paris, France. 18. Department of Urology, La Pitié Salpetrière, APHP, Paris, France. 19. University Paris 6, Faculty of Medicine Pierre and Marie Curie, Paris, France. 20. Department of Urology, Reims University Hospital, Reims, France. 21. Department of Urology, Caen University Hospital, Caen, France. 22. Department of Urology, Limoges University Hospital, Limoges, France. 23. Department of Urology, Dijon University Hospital, Dijon, France. 24. Department of Urology, Groupe hospitalier Diaconesses, Paris, France. 25. Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 26. Department of Urology, CHU Angers, Angers University Hospital, 4 rue Larrey, 49333, Angers, France. 27. Department of Urology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
Abstract
OBJECTIVES: To evaluate the oncological outcomes of papillary renal cell carcinoma (pRCC) following nephron sparing surgery (NSS) and to determine whether the subclassification type of pRCC could be a prognostic factor for recurrence, progression, and specific death. MATERIALS AND METHODS: An international multicentre retrospective study involving 19 institutions and the French network for research on kidney cancer was conducted after IRB approval. We analyzed data of all patients with pRCC who were treated by NSS between 2004 and 2014. RESULTS: We included 486 patients. Tumors were type 1 pRCC in 369 (76 %) cases and type 2 pRCC in 117 (24 %) cases. After a mean follow-up of 35 (1-120) months, 8 (1.6 %) patients experienced a local recurrence, 12 (1.5 %) had a metastatic progression, 24 (4.9 %) died, and 7 (1.4 %) died from cancer. Patients with type I pRCC had more grade II (66.3 vs. 46.1 %; p < 0.001) and less grade III (20 vs. 41 %; p < 0.001) tumors. Three-year estimated cancer-free survival (CFS) rate for type 1 pRCC was 96.5 % and for type 2 pRCC was 95.1 % (p = 0.894), respectively. Three-year estimated cancer-specific survival rate for type 1 pRCC was 98.4 % and for type 2 pRCC was 97.3 % (p = 0.947), respectively. Tumor stage superior to pT1 was the only prognostic factor for CFS (HR 3.5; p = 0.03). CONCLUSION: Histological subtyping of pRCC has no impact on oncologic outcomes after nephron sparing surgery. In this selected population of pRCC tumors, we found that tumor stage is the only prognostic factor for cancer-free survival.
OBJECTIVES: To evaluate the oncological outcomes of papillary renal cell carcinoma (pRCC) following nephron sparing surgery (NSS) and to determine whether the subclassification type of pRCC could be a prognostic factor for recurrence, progression, and specific death. MATERIALS AND METHODS: An international multicentre retrospective study involving 19 institutions and the French network for research on kidney cancer was conducted after IRB approval. We analyzed data of all patients with pRCC who were treated by NSS between 2004 and 2014. RESULTS: We included 486 patients. Tumors were type 1 pRCC in 369 (76 %) cases and type 2 pRCC in 117 (24 %) cases. After a mean follow-up of 35 (1-120) months, 8 (1.6 %) patients experienced a local recurrence, 12 (1.5 %) had a metastatic progression, 24 (4.9 %) died, and 7 (1.4 %) died from cancer. Patients with type I pRCC had more grade II (66.3 vs. 46.1 %; p < 0.001) and less grade III (20 vs. 41 %; p < 0.001) tumors. Three-year estimated cancer-free survival (CFS) rate for type 1 pRCC was 96.5 % and for type 2 pRCC was 95.1 % (p = 0.894), respectively. Three-year estimated cancer-specific survival rate for type 1 pRCC was 98.4 % and for type 2 pRCC was 97.3 % (p = 0.947), respectively. Tumor stage superior to pT1 was the only prognostic factor for CFS (HR 3.5; p = 0.03). CONCLUSION: Histological subtyping of pRCC has no impact on oncologic outcomes after nephron sparing surgery. In this selected population of pRCC tumors, we found that tumor stage is the only prognostic factor for cancer-free survival.
Authors: P Bigot; J-C Bernhard; M Crepel; K Bensalah; A-R Azzouzi; A de la Taille; L Salomon; J Tostain; V Ficarra; A-J Pantuck; A-S Belldegrun; A Méjean; J-M Ferrière; C Pfister; B Albouy; M Colombel; L Zini; A Villers; F Montorsi; S Shariat; N Rioux-Leclercq; J-J Patard Journal: Prog Urol Date: 2010-03-29 Impact factor: 0.915
Authors: Kent G Krejci; Michael L Blute; John C Cheville; Thomas J Sebo; Christine M Lohse; Horst Zincke Journal: Urology Date: 2003-10 Impact factor: 2.649
Authors: Maxime Crépel; Hendrik Isbarn; Umberto Capitanio; Daniel Liberman; Claudio Jeldres; Maxine Sun; Shahrokh F Shariat; Hugues Widmer; Philippe Arjane; Markus Graefen; Francesco Montorsi; Jean-Jacques Patard; Paul Perrotte; Pierre I Karakiewicz Journal: Urology Date: 2009-07-22 Impact factor: 2.649
Authors: Karim Bensalah; Allan J Pantuck; Nathalie Rioux-Leclercq; Rodolphe Thuret; Francesco Montorsi; Pierre I Karakiewicz; Nicolas Mottet; Laurent Zini; Roberto Bertini; Laurent Salomon; Arnaud Villers; Michel Soulie; Laurent Bellec; Pascal Rischmann; Alexandre De la Taille; Raffi Avakian; Maxime Crepel; Jean-Marie Ferriere; Jean-Christophe Bernhard; Thierry Dujardin; Frédéric Pouliot; Jérôme Rigaud; Christian Pfister; Baptiste Albouy; Laurent Guy; Steven Joniau; Hendrik van Poppel; Thierry Lebret; Thibault Culty; Fabien Saint; Amnon Zisman; Orit Raz; Hervé Lang; Romain Spie; Andreas Wille; Jan Roigas; Alfredo Aguilera; Bastien Rambeaud; Luis Martinez Piñeiro; Ofer Nativ; Roy Farfara; François Richard; Morgan Roupret; Christian Doehn; Patrick J Bastian; Stefan C Muller; Jacques Tostain; Arie S Belldegrun; Jean-Jacques Patard Journal: Eur Urol Date: 2009-03-31 Impact factor: 20.096
Authors: Michael A Gorin; Mark W Ball; Phillip M Pierorazio; Youssef S Tanagho; Sam B Bhayani; Jihad H Kaouk; Craig G Rogers; Michael D Stifelman; Ali Khalifeh; Ramesh Kumar; Ganesh Sivarajan; Mohamad E Allaf Journal: J Urol Date: 2013-06-11 Impact factor: 7.450
Authors: Stephen D W Beck; Manish I Patel; Mark E Snyder; Michael W Kattan; Robert J Motzer; Victor E Reuter; Paul Russo Journal: Ann Surg Oncol Date: 2004-01 Impact factor: 5.344
Authors: H Borgmann; M Musquera; A Haferkamp; A Vilaseca; T Klatte; S F Shariat; A Scavuzzo; M A Jimenez Rios; I Wolff; U Capitanio; P Dell'Oglio; L M Krabbe; E Herrmann; T Ecke; D Vergho; N Huck; N Wagener; S Pahernik; S Zastrow; M Wirth; C Surcel; C Mirvald; K Prochazkova; G Hutterer; R Zigeuner; L Cindolo; M Hora; C G Stief; M May; S D Brookman-May Journal: World J Urol Date: 2017-08-23 Impact factor: 4.226
Authors: Sangjun Yoo; Dalsan You; In Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim Journal: J Cancer Res Clin Oncol Date: 2017-04-27 Impact factor: 4.553
Authors: Nina Wagener; Dominic Edelmann; Axel Benner; Richard Zigeuner; Hendrik Borgmann; Ingmar Wolff; Laura M Krabbe; Mireia Musquera; Paolo Dell'Oglio; Umberto Capitanio; Tobias Klatte; Luca Cindolo; Matthias May; Sabine D Brookman-May Journal: PLoS One Date: 2017-09-21 Impact factor: 3.240